The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 2.5% during the forecast period. The major factors driving the growth of the market in the Asia region is due to growing awareness about Uterine diseases and their available therapies, increasing health care expenditure and innovation in drug development, and subsequent technological advancements.
According to Cancer Australia, estimated that in 2016, there were about 527 deaths from uterine cancer in Australia. In 2019, it was estimated at around 562 deaths. In addition, it also stated that the risk of a female dying from uterine cancer will be 1 in 205.
Furthermore, governments are provoking awareness programs in certain Asia-Pacific regions. With the growing focus of the government and the healthcare providers, it has been indicated that the market will grow rapidly over the forecast period.
Key Market Trends
Endometrial Adenocarcinoma is Expected to Witness Highest Growth Over the Forecast Period in the Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market
The major factors driving the growth of the segment is due to the growing burden of endometrial adenocarcinoma. For instance, as per Cancer Australia, in 2019, it is estimated that the age-standardized incidence rate of uterine cancer was about 20 cases per 100,000 females in Australia. The incidence rate for uterine cancer was expected to increase with age, peaking at age group 65–69.
Furthermore, as per the Journal of Gynecological Oncology 2020, endometrial cancer is a major gynecologic malignancy with the highest rate among patients with gynecologic malignant tumors in Japan. In Japan, the age-adjusted mortality rate of endometrial cancer was 2.0 in 2017. In addition, in Australia, there were about 3,115 (4.7%) new cases of uterine cancer diagnosed in 2019 as per Cancer Australia. Thus, owing to the above factors the segment is expected to show growth in the coming years.
The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is consolidated competitive and most of the companies dealing with this market are the global players. However, with the rising technological advancements, smaller companies are also focusing on market penetration and are taking efforts to grab enough market share. Some of the companies involved in the market are Merck & Co., Inc, Eisai.Co.Ltd, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, GlaxoSmithKline Plc and Novartis AG.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies
4.2.2 Increasing Health Care Expenditure
4.2.3 Innovation in Drug Development and Subsequent Technological Advancements
4.3 Market Restraints
4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs
4.3.2 High Cost Associated With the Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Endometrial Adenocarcinoma
5.1.2 Adenosquamous Carcinoma
5.1.3 Papillary Serous Carcinoma
5.1.4 Uterine Sarcoma
5.2 By Product
220.127.116.11 Radiation Therapy
18.104.22.168 Other Therapeutics
22.214.171.124 Pelvic Ultrasound
126.96.36.199 Dilation and Curettage
188.8.131.52 CT Scan
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co., Inc
6.1.3 Abbott Laboratories
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Takeda Pharmaceutical Company Limited
6.1.6 Siemens Healthcare Inc
6.1.7 GlaxoSmithKline Plc
6.1.8 Novartis AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.